Is C-reactive protein a prognostic marker after angioplasty?

Heart

Volumn 95, Issue 12, 2009, Pages 957-959

  Tousoulis, Dimitris ^a   Papageorgiou, Nikos ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; STATIN;

ANGIOPLASTY; ASSOCIATION; CHOLESTEROL BLOOD LEVEL; CORONARY STENT; DRUG ELUTING STENT; EDITORIAL; HEART INFARCTION; HUMAN; INFLAMMATION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RESTENOSIS; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY RESTENOSIS; CORONARY STENOSIS; HUMANS; PROGNOSIS;

EID: 67649231410     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.156927     Document Type: Editorial

References (22)

1. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract 2003;134:10-17.
2. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 2008;359:2195-2207
3. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-1521 (Pubitemid 29528666)
4. Versaci F, Gaspardone A, Tomai F, et al. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 2000;85:92-95 (Pubitemid 30045550)
5. Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol 2003;91:287-292 (Pubitemid 36143867)
6. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-997 (Pubitemid 32803874)
7. Palmerini T, Marzocchi A, Marrozzini C, et al. Preprocedural levels of C-reactive protein and leukocyte counts predict 9-month mortality after coronary angioplasty for the treatment of unprotected left main coronary artery stenosis. Circulation 2005;112:2332-2338 (Pubitemid 41472070)
8. Fournier JA, Delgado-Pecellín C, Cayuela A, et al. The high-sensitivity C-reactive protein level one month after bare-metal coronary stenting may predict late adverse events. Rev Esp Cardiol 2008;61:313-316 (Pubitemid 351928304)
9. Gach O, Legrand V, Biessaux Y, et al. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol 2007;99:31-35 (Pubitemid 44969338)
10. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 antiplatelet therapy in unstable angina refractory to standard treatment trial. J Am Coll Cardiol 2000;35:1535-1542
11. de Winter RJ, Koch KT, van Straalen JP, et al. Creactive protein and coronary events following percutaneous coronary angioplasty. Am J Med 2003;115:85-90. (Pubitemid 37288834)
12. Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the longterm prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002;40:1375-1382 (Pubitemid 35192859)
13. Zhou YF, Csako G, Grayston JT, et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol 1999;84:595-598 (Pubitemid 29408595)
14. Dibra A, Mehilli J, Braun S, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003;114:715-722 (Pubitemid 36776352)
15. Rittersma SZH, de Winter RJ, Koch KT, et al. Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary stent placement. Clin Chem 2004;50:1589-1596 (Pubitemid 39121227)
16. Zee RY, Hegener HH, Fernandez-Cruz A, et al. C-reactive protein gene polymorphisms and the incidence of post-angioplasty restenosis. Atherosclerosis 2004;176:393-396 (Pubitemid 39369531)
17. Kang WC, Ahn TH, Moon CI, et al. Comparison of inflammatory markers and angiographic outcomes after implantation of Rapamycin and Paclitaxel-Eluting Stents. Heart 2009;95:970-975
18. Kumar A, Cannon CP. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. J Interv Cardiol 2007;20:447-457 (Pubitemid 350179466)
19. Kubota N, Kasai T, Miyauchi K, et al. Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention. Heart Vessels 2008;23:35-39 (Pubitemid 351266887)
20. Hoshida S, Nishino M, Takeda T, et al. A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis 2004;173:285-290 (Pubitemid 38469797)
21. Gaspardone A, Versaci F, Tomai F, et al. C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol 2006;97:1311-1316
22. Kim JY, Ko YG, Shim CY, et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005;96:1384-1388 (Pubitemid 41566618)